TG Therapeutics, Inc. News Releases http://ir.tgtherapeutics.com/ TG Therapeutics, Inc. News Releases en TG Therapeutics Confirms Registration Path for Umbralisib in Marginal Zone Lymphoma Following FDA Meeting http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-confirms-registration-path-umbralisib-marginal New Drug Application (NDA) submission based on UNITY-NHL targeted for later this year NEW YORK , June 11, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the Company has confirmed its path to submit umbralisib for accelerated approval based on data from the Tue, 11 Jun 2019 07:58:00 -0400 TG Therapeutics, Inc. News Releases 15156 TG Therapeutics Presents Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 55th American Society of Clinical Oncology (ASCO) Annual Meeting http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-presents-positive-interim-data-unity-nhl-phase Overall response rate ( ORR ) of 52% (N=42), with complete response (CR) rate of 19%, by central independent review committee (IRC)  Umbralisib was well tolerated with a safety profile that appeared to be maintained with prolonged exposure NEW YORK , June 04, 2019 (GLOBE NEWSWIRE) -- TG Tue, 04 Jun 2019 16:02:00 -0400 TG Therapeutics, Inc. News Releases 15146 TG Therapeutics to Present at the Jefferies 2019 Healthcare Conference http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-present-jefferies-2019-healthcare-conference Presentation scheduled for tomorrow, Wednesday, June 5, 2019 , at 9:00 AM ET NEW YORK , June 04, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss , the Company’s Executive Chairman and Chief Executive Officer, will present at the Jefferies 2019 Tue, 04 Jun 2019 07:30:00 -0400 TG Therapeutics, Inc. News Releases 15136 TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-data-presentations-upcoming-medical Presentations include four oral and two poster presentations across three medical meetings in June NEW YORK , May 16, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 55 th American Society of Clinical Oncology ( ASCO Thu, 16 May 2019 07:30:00 -0400 TG Therapeutics, Inc. News Releases 15116 TG Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-provides-business-update-and-reports-first Conference Call to be held today, Friday, May 10, 2019 at 8:00 AM ET NEW YORK , May 10, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first quarter ended March 31, 2019 and recent company developments. Michael S. Fri, 10 May 2019 07:00:00 -0400 TG Therapeutics, Inc. News Releases 15096 TG Therapeutics to Host Conference Call on First Quarter 2019 Financial Results and Business Update http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-host-conference-call-first-quarter-2019 Conference Call to be held Friday, May 10, 2019 at 8:00 AM ET NEW YORK , May 09, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Friday, May 10, 2019 at 8:00 AM ET to discuss results for the first quarter of 2019 and provide a Thu, 09 May 2019 07:30:00 -0400 TG Therapeutics, Inc. News Releases 15086 TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Meeting http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-long-term-follow-data-phase-2-trial Ublituximab treatment continues to be well tolerated with a median duration of follow-up of 97.5 weeks NEW YORK , May 07, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases, today Tue, 07 May 2019 09:00:00 -0400 TG Therapeutics, Inc. News Releases 15076 TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Marginal Zone Lymphoma http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-receives-orphan-drug-designation-umbralisib-us NEW YORK , April 15, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics , Inc. (NASDAQ: TGTX) today announced that the U.S. Food and Drug Administration ( FDA ) granted orphan drug designation to its phosphoinositide-3-kinase (PI3K) delta inhibitor, umbralisib (TGR-1202), for the treatment of patients with Mon, 15 Apr 2019 07:30:00 -0400 TG Therapeutics, Inc. News Releases 15061 TG Therapeutics to Present at the 18th Annual Needham Healthcare Conference http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-present-18th-annual-needham-healthcare Presentation scheduled for Tuesday, April 9, 2019, at 4:50PM ET NEW YORK , April 05, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss , the Company’s Executive Chairman and Chief Executive Officer, will present at the 18 th Annual Needham Fri, 05 Apr 2019 07:30:00 -0400 TG Therapeutics, Inc. News Releases 15056 TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-reports-positive-interim-data-unity-nhl-phase-2b Overall response rate ( ORR ) of 52% (N=42), with complete response (CR) rate of 19%, by central independent review committee (IRC)  Responses were durable, with median duration of response (DOR) not reached at median 12.5 months follow-up, and all patients in complete response remain on study Mon, 01 Apr 2019 08:30:00 -0400 TG Therapeutics, Inc. News Releases 15031